The Claim
The safety profile of combination therapy with photodynamic therapy and anti-VEGF agents in polypoidal choroidal vasculopathy is comparable to monotherapy, with subretinal hemorrhage rates of ≤2% and no significant increase in adverse events.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients with polypoidal choroidal vasculopathy, combining photodynamic therapy with anti-VEGF drugs does not result in more eye complications than using either treatment alone, and serious bleeding under the retina occurs in 2% or fewer cases.
See the scientific wording
The safety profile of combination therapy with photodynamic therapy and anti-VEGF agents in polypoidal choroidal vasculopathy is comparable to monotherapy, with low rates of subretinal hemorrhage (≤2%) and no significant increase in adverse events.
The combination of treatments makes abnormal blood vessels in the eye less likely to break and bleed by strengthening their walls and stopping them from growing uncontrollably, so bleeding under the retina stays rare.
What the research says
1 studyAdding PDT to eye injections for this eye condition doesn’t make bleeding under the retina more likely — it’s just as safe as using injections alone.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.